Its agenda provided for discussion of the following:
K. Informational Item(s)
1) Discussion and Consideration of New England Compounding Center’s Contaminated Product
(39-40)
2) Discussion and Consideration as to Ther-Rx Letter (41-54)
3) Discussion and Consideration of USP Releases (55-56)
To view the entire agenda click here